TACE plus lenvatinib and tislelizumab for intermediate-stage hepatocellular carcinoma beyond up-to-11 criteria: a multicenter cohort study

Overview of attention for article published in Frontiers in immunology, July 2024

Altmetric Badge

Mentioned by

twitter: 1 X user

Citations

dimensions_citation: 1 Dimensions

Readers on

mendeley: 1 Mendeley

Summary X Dimensions citations

So far, Altmetric has seen 1 X post from an account with 33,273 followers.

New Research: TACE plus lenvatinib and tislelizumab for intermediate-stage hepatocellular carcinoma beyond up-to-11 criteria: a multicenter cohort study https://t.co/WcEJDb4Ac5 #FrontiersIn #Immunology

27 Jul 2024

Reply Repost Favourite

This page shows the most recent X posts that mention this research output.

Click here to find out how to access more activity.